File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Surgery in the era of neoadjuvant therapy for cancer of the esophagus

TitleSurgery in the era of neoadjuvant therapy for cancer of the esophagus
Authors
KeywordsEsophageal neoplasm
Combined modality therapy
Esophagectomy
Issue Date2016
Citation
Esophagus, 2016, v. 13, n. 2, p. 105-109 How to Cite?
Abstract© 2016, The Japan Esophageal Society and Springer Japan. Multimodality treatment strategies have become commonplace and stand-of-care in the management of esophageal cancer. In Japan, preoperative chemotherapy is routine, while in many centers around the globe chemoradiotherapy is widely practiced. How surgery should be integrated and the manner in which esophagectomy should be carried out remain controversial. From the literature, it seems that esophagectomy for salvage after definitive chemoradiotherapy is associated with increased morbidity rates. In the neoadjuvant setting, however, where less chemotherapy and lower dose of radiotherapy is usually given, results are comparable with upfront surgery. Video-assisted thoracoscopic esophagectomy is also safe after neoadjuvant therapy; special adjunct like recurrent laryngeal nerve monitoring may be helpful for extended mediastinal lymphadenectomy. There is not enough evidence to suggest that lesser degree of lymphadenectomy is required after neoadjuvant therapy. As such the same degree of nodal dissection is recommended. Further work is required to delineate the role of surgery in multimodality treatment programs.
Persistent Identifierhttp://hdl.handle.net/10722/244226
ISSN
2015 Impact Factor: 0.386
2015 SCImago Journal Rankings: 0.213

 

DC FieldValueLanguage
dc.contributor.authorWong, Ian Yu Hong-
dc.contributor.authorLaw, Simon-
dc.date.accessioned2017-08-31T08:56:23Z-
dc.date.available2017-08-31T08:56:23Z-
dc.date.issued2016-
dc.identifier.citationEsophagus, 2016, v. 13, n. 2, p. 105-109-
dc.identifier.issn1612-9059-
dc.identifier.urihttp://hdl.handle.net/10722/244226-
dc.description.abstract© 2016, The Japan Esophageal Society and Springer Japan. Multimodality treatment strategies have become commonplace and stand-of-care in the management of esophageal cancer. In Japan, preoperative chemotherapy is routine, while in many centers around the globe chemoradiotherapy is widely practiced. How surgery should be integrated and the manner in which esophagectomy should be carried out remain controversial. From the literature, it seems that esophagectomy for salvage after definitive chemoradiotherapy is associated with increased morbidity rates. In the neoadjuvant setting, however, where less chemotherapy and lower dose of radiotherapy is usually given, results are comparable with upfront surgery. Video-assisted thoracoscopic esophagectomy is also safe after neoadjuvant therapy; special adjunct like recurrent laryngeal nerve monitoring may be helpful for extended mediastinal lymphadenectomy. There is not enough evidence to suggest that lesser degree of lymphadenectomy is required after neoadjuvant therapy. As such the same degree of nodal dissection is recommended. Further work is required to delineate the role of surgery in multimodality treatment programs.-
dc.languageeng-
dc.relation.ispartofEsophagus-
dc.subjectEsophageal neoplasm-
dc.subjectCombined modality therapy-
dc.subjectEsophagectomy-
dc.titleSurgery in the era of neoadjuvant therapy for cancer of the esophagus-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s10388-016-0523-y-
dc.identifier.scopuseid_2-s2.0-84957570831-
dc.identifier.volume13-
dc.identifier.issue2-
dc.identifier.spage105-
dc.identifier.epage109-
dc.identifier.eissn1612-9067-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats